Malaria Management
For uncomplicated P. falciparum malaria, treat with oral artemisinin-based combination therapy (ACT) such as artemether-lumefantrine or dihydroartemisinin-piperaquine; for severe malaria, immediately initiate intravenous artesunate regardless of patient age or pregnancy status. 1
Diagnosis
Perform immediate parasitological confirmation with thick and thin blood smears (Giemsa-stained) as the gold standard. Rapid diagnostic tests (RDTs) can serve as initial screening but must not replace urgent microscopy, which should run in parallel 2. Do not delay treatment if microscopy is unavailable in suspected severe cases 3.
Key diagnostic points:
- Fever is present in almost all non-immune patients
- Travel history to endemic areas is mandatory in any febrile patient
- Thrombocytopenia and anemia are common laboratory findings
- Migrants from endemic areas may present with minimal symptoms 1
Treatment of Uncomplicated Malaria
P. falciparum (Uncomplicated)
First-line treatment options:
Monitor parasitemia every 12 hours until decline to <1%, then every 24 hours until negative. Check complete blood count, hepatic, renal, and metabolic panels daily 1.
P. vivax, P. ovale, P. malariae
Either chloroquine OR oral ACT can be used 1, 2. Critically, for P. vivax and P. ovale, add an 8-aminoquinoline (primaquine or tafenoquine) concomitantly to eliminate liver hypnozoites 1.
Important caveat: Test for G6PD deficiency before primaquine or tafenoquine, though single-dose gametocytocidal primaquine does not require G6PD testing 3.
Treatment of Severe Malaria
Intravenous artesunate is the definitive treatment for severe malaria in all patients, including pregnant women (all trimesters) and children 1, 3, 2.
Criteria for severe malaria include:
- Altered consciousness/coma
- Severe anemia
- Renal impairment
- Hypoglycemia
- Acidosis (elevated lactate, reduced bicarbonate)
- High parasitemia (>10-15%)
- Jaundice
- Respiratory distress 1
Management protocol:
- Admit to intensive care unit
- Administer IV artesunate for 3 doses
- Switch to oral ACT when parasitemia <1% and patient can tolerate oral therapy
- Monitor for delayed hemolysis on days 7,14,21, and 28 post-artesunate 1, 2
This delayed hemolysis monitoring is critical as artesunate causes more rapid parasite clearance than quinine, potentially leading to hemolytic complications weeks later.
Special Populations
Pregnant Women
For uncomplicated malaria in first trimester: Oral quinine plus clindamycin remains recommended by many guidelines, though this reflects older evidence 4. However, for severe malaria, IV artesunate should be used in all trimesters without hesitation 3, 4.
For second and third trimesters with uncomplicated disease, artemether-lumefantrine is appropriate 4.
Children
Standard ACT regimens (weight-adjusted dosing) for uncomplicated malaria and IV artesunate for severe disease apply to pediatric patients 3, 2.
Prophylaxis for Travelers
Personal Protection Measures
- Use insecticide-treated bed nets (permethrin-impregnated)
- Apply DEET-containing repellents to exposed skin
- Wear long-sleeved clothing and long trousers after sunset
- Use electric mats to vaporize synthetic pyrethroids 5
Chemoprophylaxis Options
For areas with chloroquine-sensitive malaria:
- Chloroquine 300 mg base weekly 5
For chloroquine-resistant areas (most of sub-Saharan Africa, Southeast Asia):
- Atovaquone-proguanil (daily dosing)
- Mefloquine 250 mg weekly (avoid in those with psychiatric history, seizure disorders, or requiring precision movements) 5, 6
- Doxycycline 100 mg daily (avoid excessive sun exposure due to photosensitization risk) 5
Critical compliance points:
- Start prophylaxis 1 week before travel (2-3 weeks for mefloquine)
- Continue for 4 weeks after leaving endemic area
- Most deaths occur in non-compliant travelers 5
Standby Treatment
For travelers to remote areas without immediate medical access, carry artemether-lumefantrine or atovaquone-proguanil for self-treatment if fever develops. Seek medical attention immediately after self-treatment 5.
Common Pitfalls
- Delayed diagnosis: Most preventable deaths result from failure to consider malaria in febrile returned travelers 1
- Species misidentification: P. ovale and P. cynomolgi can be mistaken for P. vivax; always confirm with expert microscopy 7, 8
- Forgetting hypnozoite treatment: P. vivax/ovale require primaquine to prevent relapses 1
- Premature discharge: Even uncomplicated cases require close monitoring until parasitological cure 2
- Mefloquine neuropsychiatric effects: Occur in first 3 doses (70% of cases); screen for contraindications 5